by EpicentRx | Sep 1, 2023 | Conferences
November 2023; Boston, Massachusetts Oral Presentation: The Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases
by EpicentRx | Sep 1, 2023 | Conferences
November 2023; Washington D.C. Oral Presentation: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson’s disease
by EpicentRx | Sep 1, 2023 | Conferences
June 2023; Chicago, Illinois Poster: RRX-001 Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001 TGF-ß Trap (NCT04673942) Poster: RRX-001, KEVLARx: A phase 2b, multi-institutional, randomized,...
